Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas

The American Journal of Surgical Pathology
Erika M MooreSarah E Gibson

Abstract

Myocyte enhancer binding factor 2B (MEF2B) is a transcriptional activator of the BCL6 proto-oncogene in normal germinal center (GC) B-cells. Limited data exists concerning its expression in B-cell lymphomas, and comparison with other GC-associated antigens is lacking. Its role in the differential diagnosis of B-cell lymphomas, particularly in the distinction of follicular lymphoma (FL) versus marginal zone lymphoma (MZL), remains to be determined. We evaluated MEF2B expression, in comparison with additional GC markers, LIM domain-only transcription factor 2 (LMO2), and human GC-associated lymphoma (HGAL), in a variety of B-cell lymphomas, with particular emphasis on their utility in differentiating FL from MZL. MEF2B was positive in all FL and Burkitt lymphomas, 8/9 mantle cell lymphomas, 2/24 splenic MZL, 1/10 chronic lymphocytic leukemia/small lymphocytic lymphomas, and 38/44 diffuse large B-cell lymphoma (DLBCL), but was negative in all extranodal MZL of mucosa-associated lymphoid tissue, nodal MZL, and B-lymphoblastic lymphomas. Focusing on low-grade FL versus MZL, MEF2B was 100% sensitive and 95% specific for FL, which was similar to BCL6, but superior to LMO2 (sensitivity 87%, specificity 86%) and HGAL (sensitivity 97%, s...Continue Reading

References

Mar 21, 1998·The American Journal of Surgical Pathology·E BallesterosA Y Matsushima
Sep 18, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J R AndersonD D Weisenburger
Feb 26, 2000·Journal of Clinical Pathology·E K MillarS Braye
Dec 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yasodha NatkunamIzidore S Lossos
Jan 2, 2008·Haematologica·Hongtao YeMing-Qing Du
Jun 14, 2008·American Journal of Clinical Pathology·Melinda A PatersonPaul B Coughlin
Oct 20, 2009·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Joel F GradowskiSteven H Swerdlow
Oct 30, 2009·American Journal of Clinical Pathology·Mohamed E SalamaYasodha Natkunam
Dec 17, 2009·Human Pathology·Scott D DufresneSteven H Swerdlow
Aug 24, 2012·Applied Immunohistochemistry & Molecular Morphology : AIMM·Jennifer Chapman-FredricksIzidore S Lossos
Sep 10, 2014·Applied Immunohistochemistry & Molecular Morphology : AIMM·Thomas MenterAlexandar Tzankov
Jun 20, 2015·Virchows Archiv : an International Journal of Pathology·Dóra KrenácsLászló Krenács
Jan 23, 2016·American Journal of Clinical Pathology·Dragan JevremovicEllen D McPhail
Mar 14, 2017·The American Journal of Surgical Pathology·Luis ColomoUNKNOWN Grup per l’Estudi dels Limfomes de Catalunya i Balears (GELCAB)

❮ Previous
Next ❯

Citations

May 21, 2019·Oncotarget·Kiran MadugulaPooja Jain
Dec 19, 2019·Applied Immunohistochemistry & Molecular Morphology : AIMM·Abeer SalamaSiraj M El Jamal
Nov 18, 2018·Laboratory Investigation; a Journal of Technical Methods and Pathology·Siraj M El JamalMohamed Hassan
Aug 9, 2020·Journal of Clinical Pathology·Kohei FujikuraYukihiro Imai
Oct 13, 2020·Human Pathology·Nicholas J K BaraschSteven H Swerdlow

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.